Supplemental Table 2. Derived sirukumab pharmacokinetic parameters

PK Parameters	Part A*		Part B							
	First Dose	6th Dose	First Dose				Last dose			
	100 mg every 2 weeks	100 mg every 2 weeks	100 mg every 2 weeks	100 mg every 4 weeks	50 mg every 4 weeks	25 mg every 4 weeks	100 mg every 2 weeks	100 mg every 4 weeks	50 mg every 4 weeks	25 mg every 4 weeks
n	14	11	29	29	28	31	26	22	21	28
C_{max} (µg/mL)	7.50 (2.91)	20.01 (4.40)	6.60 (3.03)	6.73 (2.73)	2.99 (1.51)	1.86 (1.11)	15.68 (7.07)	9.34 (4.31)	4.26 (1.73)	2.93 (1.29)
t_{max} (day)	3.9 [2.2, 13.8]	4.0 [3.0, 7.0]	4.9 [2.8, 10.7]	5.0 [3.0, 13.9]	5.4 [2.9, 12.6]	5.0 [2.9, 27.8]	5.0 [0, 9.7]	4.0 [0, 7.1]	5.0 [0, 7.0]	4.0 [2.8, 11.7]
$AUC_{(t1-t2)}$ (µg.day/mL)†	80.63 (25.66)	232.43 (48.90)	66.03 (31.62)	107.88 (43.05)	49.38 (23.15)	29.08 (10.65)	188.67 (90.43)	172.04 (86.17)	83.52 (35.17)	52.02 (22.03)
$t_{1/2}$ (day)	NA	18.3 (4.5)	NA	NA	NA	NA	19.0 (4.3)	16.0 (4.1)	16.1 (4.8)	14.9 (4.5)
R_{Cmax}	NA	2.7 (1.1)	NA	NA	NA	NA	2.6 (1.0)	1.5 (0.9)	1.7 (0.6)	1.6 (0.6)
$R_{AUC(0-14d)}$	NA	2.7 (0.5)	NA	NA	NA	NA	3.0 (1.2)	1.6 (0.8)	1.8 (0.6)	1.7 (0.4)

Data presented as mean (SD) or median [range] unless noted otherwise. * Data from one of the study sites that participated in Part A were excluded from all pharmacokinetics analyses due to questionable data integrity. † $AUC_{(t1-t2)}$, area under the serum concentration versus time curve between 2 defined sampling timepoints (AUC_{0-14d} was reported for the every-2-week treatment group; AUC_{0-28d} was reported for q4w treatment groups); PK, pharmacokinetic; C_{max}, observed maximum serum concentration; NA, not available; $R_{AUC(t1-t2)}$, accumulation ratio calculated from $AUC_{(t1-t2)}$ after the last dose of multiple doses and $AUC_{(t1-t2)}$ after the first dose; R_{Cmax}, accumulation ratio calculated from C_{max} after the last dose of multiple doses and C_{max} after the first dose; $t_{1/2}$, terminal half-life; t_{max}, observed time to reach maximum serum concentration.